Abstract:Human adenoviruses (HAdVs) are important tools for vector development for applications such as immunization, oncolytic therapy, or gene therapy. However, their potential is limited by preexisting immunity against HAdV; therefore, it is important for future vector design to identify HAdV types of low seroprevalence. To provide such data, we performed an analysis of both binding and neutralizing antibodies in sera from three student cohorts. Among these young adults, we found the highest levels of binding antibodies against HAdV-C1, -D33, -A31, -B35, -C5, -D26, -E4, and -B7. The highest levels of neutralizing antibodies were detected against HAdV-C2, -B3, -C1, -F41, -G52, -C5, -A31, -E4, and -C6. While binding and neutralizing antibody levels were not different in males and females or in samples collected before and after the cold season, we found significantly lower levels of binding antibodies in sera collected 20 months after the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, indicating a waning of HAdV-specific antibody responses on that time scale. Our data indicate that mainly HAdV types of species A, B, and D show low seroprevalence with regard to both binding and neutralizing antibodies and may represent good candidates for further characterization and future development as novel vector systems. IMPORTANCE Vectors based on human adenoviruses (HAdVs) are important for the development of novel immunizations, oncolytic therapies, and gene therapies. The use of HAdV-based vaccines against Ebola virus, the rapid adaptation of the vector technology for vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and their very good efficacy have shown the great potential of HAdV-based vaccines. Preexisting immunity against HAdV-based vectors can limit their efficacy significantly; therefore, it is highly desirable to identify HAdV types with low seroprevalence. The identification of new suitable HAdV types for vector development will broaden the repertoire and contribute to future epidemic preparedness.

A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011

Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China.

Epidemiology of Adenovirus Type 5 Neutralizing Antibodies in Healthy People and AIDS Patients in Guangzhou, Southern China.

Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China

[Epidemiological Study of Human Type 5 Adenovirus in Guangzhou Using Chemiluminescence for Neutralizing Antibody Assay].

Seroprevalence of Neutralizing Antibodies Against Adenovirus Type 14 and 55 in Healthy Adults in Southern China

The Epidemiology of Adenovirus Associated Lower Respiratory Tract Infection in Hospitalized Children in Hangzhou City, China

Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China <subtitle>Prevalence of Ad14 and 55-neutralizing antibodies</subtitle>

Seroprevalence of Neutralizing Antibodies to Human Adenovirus Type 4 and 7 in Healthy Populations from Southern China

Epidemiological analysis of human adenovirus in children diagnosed with acute respiratory tract infection.

Neutralizing Antibody Responses to Enterovirus and Adenovirus in Healthy Adults in China

The Sero-Prevalence of Anti-Adenovirus 5 Neutralizing Antibodies is Independent of a Chronic Hepatitis B Carrier State in China

A Bivalent Live-Attenuated Vaccine Candidate Elicits Protective Immunity Against Human Adenovirus Types 4 And 7

Adenovirus Infection in Children with Acute Lower Respiratory Tract Infections in Beijing, China, 2007 to 2012

Prevalence of adenovirus in children with acute respiratory tract infection in Lanzhou, China

Adenovirus Infection Rate of Chinese Children with Respiratory Diseases: A Meta-analysis

Epidemiology of human adenovirus infection in children hospitalized with lower respiratory tract infections in Hunan, China

Immunogenicity, Safety, and Immune Persistence of One Dose of SARS-CoV-2 Recombinant Adenovirus Type-5 Vectored Vaccine in Children and Adolescents Aged 6–17 Years: An Immunobridging Trial

Analysis of the Prevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Student Cohorts Reveals Low-Prevalence Types and a Decline in Binding Antibody Levels during the SARS-CoV-2 Pandemic

[Monocytes Are More Susceptible in Vitro in Rhesus Macaques of Chinese Origin to Recombinant Serotype 5 Adenovirus with Higher Preexisting Vector Specific Neutralizing Antibody Titer].

Human adenoviruses in paediatric patients with respiratory tract infections in Beijing, China